Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortization of GoodwillAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maravai Lifesciences Holdings (MRVI) Depreciation & Amortization (CF) (2020 - 2025)

Historic Depreciation & Amortization (CF) for Maravai Lifesciences Holdings (MRVI) over the last 6 years, with Q3 2025 value amounting to $6.0 million.

  • Maravai Lifesciences Holdings' Depreciation & Amortization (CF) rose 1845.76% to $6.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $23.1 million, marking a year-over-year increase of 1976.71%. This contributed to the annual value of $20.9 million for FY2024, which is 6201.55% up from last year.
  • Per Maravai Lifesciences Holdings' latest filing, its Depreciation & Amortization (CF) stood at $6.0 million for Q3 2025, which was up 1845.76% from $6.0 million recorded in Q2 2025.
  • Maravai Lifesciences Holdings' 5-year Depreciation & Amortization (CF) high stood at $6.0 million for Q3 2025, and its period low was $1.3 million during Q1 2021.
  • Over the past 5 years, Maravai Lifesciences Holdings' median Depreciation & Amortization (CF) value was $2.8 million (recorded in 2023), while the average stood at $3.4 million.
  • Its Depreciation & Amortization (CF) has fluctuated over the past 5 years, first tumbled by 2572.44% in 2021, then skyrocketed by 13009.62% in 2024.
  • Quarter analysis of 5 years shows Maravai Lifesciences Holdings' Depreciation & Amortization (CF) stood at $1.7 million in 2021, then grew by 14.38% to $2.0 million in 2022, then soared by 97.09% to $3.9 million in 2023, then surged by 40.16% to $5.5 million in 2024, then increased by 8.36% to $6.0 million in 2025.
  • Its last three reported values are $6.0 million in Q3 2025, $6.0 million for Q2 2025, and $5.7 million during Q1 2025.